Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial 1. Patients receiving landiolol were more likely to achieve target heart rates of 60-94 following sepsis-related tachyarrhythmia and had significantly reduced incidence of new onset arrhythmia Evidence Rating: 1 (Excellent) Sepsis associated tachyarrhythmias […]
Source: 2 Minute Medicine
